Core Viewpoint - Senti Biosciences reported promising data from its Phase 1 trial of SENTI-202 in R/R AML, leading to a significant stock price increase of over 7% [1] Group 1: Clinical Data - The trial showed a total overall response rate (ORR) of 50% [1] - The complete response/complete hematologic response (CR/CRh) rate was 42% [1] - Most patients demonstrated a durable response with minimal residual disease negativity (MRD-Negative) [1] Group 2: Regulatory Support - Senti Biosciences received Regenerative Medicine Advanced Therapy (RMAT) designation to advance the study to pivotal research [1]